Abscesser er en vanlig medisinsk tilstand i både human- og veterinærmedisin forårsaket av bakterielle infeksjoner, traumer eller postoperativt. Dagens behandling av abscesser er skylling og drenering, men denne prosessen kan ta lang tid og mange pasienter får snart tilbakefall.
Etter mange års erfaring på området har forskeren Sverre Nesvåg og legen Tore Tholfsen, begge tilknyttet Stavanger universitetssykehus (SUS), kommet med en ny type kateter for abscessdrenering. Dette kateteret kombinerer kunnskap fra medisin og olje og gass, og noen av dets funksjoner har blitt patentert i 2021.
Validé Technology Transfer Office (TTO) bidrar til å utvikle og kommersialisere dette produktet.
The aim of this project is to create a medical prototype for drainage of abscesses and test its functionality in animal models. The prototype will consist in a modified catheter with the capacity for better rinsing and waste fluid collection, which makes the drainage faster and more efficient, preventing future relapses which nowadays are common in the clinical practice.
Abscesses are a common medical condition in both human and veterinary medicine and can be caused by bacterial infections, trauma or post operatively. The current medical practice is rudimentary. In addition, the treatment of this particular condition is treated both at the surgical department and interventional radiology department at most of the hospitals, which undermines the interest of the practitioners in finding better solutions. The inventors involved in this project have experienced the difficulties and have come up with a better solution for optimal drainage of this condition.
The ultimate goal is to connect this innovative catheter with the right equipment for achieving automatization of the procedure for more efficient and better controlled rinsing. Higher success rates in abscess drainage will improve well-being, reduce hospitalizations and time spent in hospital, decrease the frequency of reinterventions and lower the risk of complications such as sepsis, pain and bleeding.
A priority patent was granted in Sweden in March 2021. The patent description for the MADS solution was made public in April 2021. There is a European process under examination since April 2022.